Results 121 to 130 of about 2,266,477 (255)

KIT Mutant/Core binding factor-negative acute myeloid leukemia might be a complex subgroup with dismal prognosis: a single-center retrospective analysis

open access: yesAnnals of Hematology
KIT mutations are well-established as poor prognostic markers in core binding factor AML (CBF AML). However, data on KIT mutation in CBF-negative (CBF-neg) AML remains scarce.
Rui Jiang   +8 more
doaj   +1 more source

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito   +8 more
wiley   +1 more source

Infectious Diseases Pathology Branch [PDF]

open access: yes
IDPB conducts investigations and studies of infectious diseases of unknown cause or origin to help identify previously unrecognized or new infectious agents.CS256582-APublication date from document properties.Infectious-Disease-Pathology-factsheet-7-2015.

core  

Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations

open access: yesJournal of Translational Medicine
Background Patients with refractory/relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL) harboring TP53 alterations have a dismal prognosis due to profound chemoresistance. While CD19 chimeric antigen receptor T-cell (CAR-T) therapy has shifted the
Yutong Tang   +9 more
doaj   +1 more source

Predictive Value of Composite Inflammatory Markers for Stroke Prognosis: A Prospective Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Novel composite inflammatory markers' role in stroke prognosis is understudied, and the best predictor is unclear, requiring further exploration. Objectives This study aimed to systematically evaluate the associations of 6 novel composite inflammatory markers on stroke prognosis.
Bing Wu   +7 more
wiley   +1 more source

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui   +10 more
wiley   +1 more source

Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy

open access: yesnpj Precision Oncology
The abnormal expression of the HOXA genes is intricately associated with the pathogenesis and progression of acute myeloid leukemia (AML), as these genes are crucial in regulating cellular differentiation and proliferation during normal hematopoiesis. In
Wusixian Huang   +4 more
doaj   +1 more source

Diffuse MRI Edema Predicts Relapse in Cerebral Amyloid Angiopathy–Related Inflammation

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify MRI predictors of relapse and quantify relapse and mortality risk in cerebral amyloid angiopathy–related inflammation (CAA‐RI). A secondary objective was to assess the association between mycophenolate mofetil use and relapse risk. Methods We performed a retrospective cohort study of 36 patients with CAA‐RI treated at the
G. Abbas Kharal   +10 more
wiley   +1 more source

CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months

open access: yesBlood Cancer Journal, 2023
Zhenzhen Yao   +14 more
doaj   +1 more source

Developing and Evaluating a Laboratory‐Based Frailty Index for the Prediction of Long‐Term Health Outcomes in Systemic Lupus Erythematosus

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to construct and evaluate the first laboratory‐based frailty index (FI‐Lab) for predicting adverse outcomes in systemic lupus erythematosus (SLE) and to compare its predictive ability to that of an existing clinical FI. Methods We used data from a single‐center prospective cohort of adult patients with SLE whose baseline visit ...
Grace Burns   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy